Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28824070 | 0.88 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL4367412 | 0.76 | ALDH1A1 (0.34) | ALDH1A1TSHRAURKA | |
| SCHEMBL27961324 | 0.71 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL3844719 | 0.70 | ALDH1A1 (0.38) | ALDH1A1TSHRAURKA | |
| SCHEMBL18151130 | 0.68 | GAA (0.34) | — | |
| SCHEMBL22405796 | 0.67 | ALDH1A1 (0.38) | ALDH1A1TSHRAURKA | |
| SCHEMBL34473961 | 0.67 | POLB (0.40) | ALDH1A1TSHRAURKA | |
| SCHEMBL27909742 | 0.67 | KCNN4 (0.46) | ALDH1A1TSHRKCNN4KCNA3AURKA | |
| SCHEMBL24112327 | 0.67 | ALDH1A1 (0.34) | ALDH1A1TSHRAURKA | |
| SCHEMBL3147317 | 0.67 | GABRP (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991987-B1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-9505762-B2 | Purine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2991987-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160046631-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014177490-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046631-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | CNR1, CNR2, P2RY1 | ALDH1A1 1306/4885TSHR 450/4885KCNN4 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.